GlassScriptPhysician profile
Adam B Blickley
NPI 1679554679
$3,455.91
in general payments reported to CMS, 2019-2025
33 companies · $518 in 2025
The $518 reported for 2025 was more than what 81% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $471 · 2020: $174 · 2021: $519 · 2022: $699 · 2023: $691 · 2024: $384 · 2025: $518.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,593.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,592.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Hologic Sales and Service, LLC | $586.76 | 2019-2025 | Myosure Tissue Removal Device, Novasure, Coolseal Generator |
| Abbvie INC. | $559.85 | 2019-2024 | Orilissa, Lo Loestrin Fe, Viberzi |
| Astellas Pharma US INC | $342.34 | 2019-2025 | Veozah |
| Daiichi Sankyo INC. | $259.20 | 2019-2025 | Injectafer |
| Mayne Pharma Commercial LLC | $218.92 | 2022-2025 | |
| Aspira Women'S Health INC | $212.36 | 2022-2025 | Ova1 |
| Bayer Healthcare Pharmaceuticals INC. | $187.72 | 2019-2024 | |
| Organon LLC | $120.32 | 2023-2025 | Nexplanon, Nuvaring |
| Merck Sharp & Dohme LLC | $116.87 | 2019-2025 | Gardasil 9, Gardasil |
| Sumitomo Pharma America, INC. | $102.37 | 2023-2025 | Myfembree, Gemtesa |
| Amag Pharmaceuticals, INC. | $96.93 | 2019-2020 | |
| Exeltis, USA INC. | $87.45 | 2022-2025 | Slynd |
| Channel Medsystems, INC. | $61.16 | 2025 | |
| Biogen, INC. | $46.33 | 2025 | Zurzuvae |
| Pfizer INC. | $38.15 | 2022 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Becton, Dickinson and Company | $37.07 | 2023-2024 | Bd Onclarity |
| Myovant Sciences INC. | $36.84 | 2021 | |
| Coloplast Corp | $36.04 | 2020 | |
| Vertical Pharmaceuticals, LLC | $32.92 | 2019-2020 | |
| Allergan, INC. | $32.73 | 2019-2020 | |
| Axonics, INC. | $30.13 | 2022-2023 | Axonics |
| Biohaven Pharmaceutical Holding Company LTD. | $29.01 | 2022 | |
| Medline Industries LP | $21.86 | 2022 | |
| Medtronic, INC. | $19.84 | 2023 | Truclear |
| Medicem INC. | $19.22 | 2024 | |
| Pacira Pharmaceuticals Incorporated | $19.17 | 2022 | |
| Coopersurgical, INC. | $18.21 | 2022 | |
| Shield Therapeutics INC | $17.28 | 2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $16.33 | 2020 | |
| Ibsa Pharma INC. | $14.67 | 2022 | |
| Mallinckrodt Enterprises LLC | $14.08 | 2019 | |
| Evofem Biosciences, INC. | $12.04 | 2022 | |
| Roche Diagnostics Corporation | $11.74 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Adam Blickley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.